Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1/2 2Phase NA 1Phase 1 1

Status

Recruiting 2

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Carcinoma, Non-Small-Cell Lung 256Breast Neoplasms 174Neoplasms 169Colorectal Neoplasms 153Neoplasm Metastasis 127Recurrence 120Melanoma 120Prostatic Neoplasms 118Leukemia, Myeloid, Acute 117Pancreatic Neoplasms 115Ovarian Neoplasms 112Multiple Myeloma 104Lung Neoplasms 94Stomach Neoplasms 92Triple Negative Breast Neoplasms 86Squamous Cell Carcinoma of Head and Neck 85Glioblastoma 81Lymphoma 77Lymphoma, Non-Hodgkin 75Lymphoma, Large B-Cell, Diffuse 65Precursor Cell Lymphoblastic Leukemia-Lymphoma 64Carcinoma, Renal Cell 64Advanced Solid Tumor 59Endometrial Neoplasms 58Carcinoma, Hepatocellular 58Small Cell Lung Carcinoma 56Uterine Cervical Neoplasms 53Sarcoma 53Myelodysplastic Syndromes 51Leukemia 50

Interventions

contrast agent BR1 1Biopsy 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Neoplasms, Nerve Tissue × 1 year × Clear all
NCT07416188 2026-06-03

Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
40 enrolled
CNS

Brain Neoplasms, Glioblastoma, Glioma, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Nerve Tissue, Recurrence, Central Nervous System Neoplasms

NCT06329570 2026-04-09

Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)

NaviFUS Corporation

Phase 1/2 Recruiting
10 enrolled
CNS

Brain Neoplasms, Glioblastoma, Glioma, Neoplasms, Neoplasms, Nerve Tissue

Data powered by HemOnc (CC BY 4.0) Colophon âš¡